Neoadjuvant therapy in early-stage non-small cell lung cancer: A real-world analysis
Open Access
- 24 October 2024
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 198, 107997
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB–IIIB NSCLCClinical Lung Cancer, 2024
- Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung CancerJournal of Thoracic Oncology, 2024
- Neoadjuvant Chemoimmunotherapy for NSCLCJAMA Oncology, 2024
- The Landsteiner lung cancer research platform (LALUCA)Wiener klinische Wochenschrift, 2024
- Unresectable Stage III NSCLC Can Be Reevaluated for Resectability After Initial TreatmentJournal of Thoracic Oncology, 2023
- Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN TrialClinical Lung Cancer, 2022
- Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapyAnnals of Oncology, 2021
- Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experienceLung Cancer, 2021
- Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trialThe Lancet Oncology, 2020
- Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methodsInternational Journal of Cancer, 2018